In the past two decades, LC-MS/MS has been the standard platform for therapeutic drug quantitation in a regulated environment, owing to its sensitivity, selectivity, and ruggedness. While development of high resolution HPLC, better sample preparation practices, and improved detection limit for mass spectrometer have made much regulated bioanalytical challenges less daunting, areas of challenges remain. Dramatic evolution of discovery pipeline has created unprecedented demands on bioanalytical organizations. Novel modalities such as LDDS are extremely time consuming and technical challenging to support. Current generation of these molecules are larger relative to their chiral centers, resulting in longer run time. At BMS, we have been successful in optimizing methods to support these compounds. This presentation will be centered on how next generation separation techniques such as SFC will impact these modalities.
Learning Objectives:
Upon completion, participant will be able to comprehend the recent novel bioanalytical methodologies in support of the emerging new modalities.
Upon completion, participant will be able to address the recent demanding bioanalytical challenges and understand what strategy to move forward with.
Upon completion, participant will be able to learn the bioanalytical perspectives from industrial scientists and leaders across a variety of drug therapeutic areas.